Top

Published in:

01-04-2020 | Metastasis | Original Article

The Association between Epidermal Growth Factor Receptor Single Nucleotide Polymorphisms and Radiochemotherapy Response in Cervical Cancer

Authors: Ge Jin, Xiao-Mei Fan, Kui-Xiu Li, Shu-Huai Niu, Qian-Ying Zhang

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

Emerging data reveal that epidermal growth factor receptor (EGFR) single nucleotide polymorphisms (SNPs) can act as efficacy indicators for tumor treatment. Here, the association between EGFR R497K (rs11543848) and -216G/T (rs712829) SNPs and radiochemotherapy response in cervical cancer was investigated. EGFR R497K and -216G/T genotypes were analyzed by polymerase chain reaction-ligation detection reaction in 196 cervical cancer patients receiving radiotherapy alone, or in combination with chemotherapy. Compared with the 497G/G genotype, the A/A genotype significantly increased sensitivity to radiochemotherapy treatment (adjusted OR = 0.244, 95% CI = 0.087–0.680). Sensitivity to radiochemotherapy was not significantly different in carriers of the ‘T’ allele than that measured for the -216G/G genotype (adjusted OR = 2.412, 95% CI = 0.856–6.979). Additionally, the 497A/A genotype conferred a reduced risk of recurrence or metastasis than did the G/G genotype (adjusted OR = 0.248, 95% CI = 0.078–0.786, P < 0.05). Moreover, carriers of the ‘T’ allele did not have significantly modified risk of recurrence or metastasis compared with those with the -216G/G genotype (adjusted OR = 1.027, 95% CI = 0.324–3.253). Multivariate analysis revealed an association between clinical stage and treatment response (adjusted OR = 3.575, 95% CI = 1.662–7.692) and between age and the risk of recurrence or metastasis (adjusted OR = 0.319, 95% CI = 0.148–0.691). Our results show that, in patients with cervical cancer, the R497K polymorphism is correlated with treatment response and the risk of recurrence or metastasis. The R497K SNP might be a genetic marker for prediction of radiochemotherapy response and the risk of recurrence and/or metastasis in patients with cervical cancer.

Lee KB, Shim SH, Lee JM (2018) Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis. J Gynecol Oncol 29

Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, Kerkar R, Engineer R, Tongaonkar H, Ghosh J, Gulia S, Kumar N, Shylasree TS, Gawade R, Kembhavi Y, Gaikar M, Menon S, Thakur M, Shrivastava S, Neoadjuvant BR (2018) Chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical Cancer: a randomized controlled trial. J Clin Oncol:JCO2017759985

Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F (2002) Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 20:179–188CrossRef

Cerciello F, Riesterer O, Sherweif M, Odermatt B, Ciernik IF (2007) Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? Gynecol Oncol 106:394–399CrossRef

Fukazawa EM, Baiocchi G, Soares FA, Kumagai LY, Faloppa CC, Badiglian-Filho L, Coelho FR, Goncalves WJ, Costa RL, Goes JC (2014) Cox-2, EGFR, and ERBB-2 expression in cervical intraepithelial neoplasia and cervical cancer using an automated imaging system. Int J Gynecol Pathol 33:225–234CrossRef

Hernowo BS, Suryanti S, Wibisono F (2016) Correlation between EGFR expression and Radiosensitivity in cervical adenocarcinoma cases. Asian Pac J Cancer Prev 17:2535–2537PubMed

Hu S, Fu W, Li T, Yuan Q, Wang F, Lv G, Lv Y, Fan X, Shen Y, Lin F, Tang Y, Ye X, Yang Y, Lei C (2017) Antagonism of EGFR and notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Sci Transl Med 9:eaag0339CrossRef

Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS, Gurtner K, Krause M, Baumann M, Kang JX, Whetstine JR, Willers H (2017) Radiation resistance in KRAS-mutated lung Cancer is enabled by stem-like properties mediated by an Osteopontin-EGFR pathway. Cancer Res 77:2018–2028CrossRef

Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM (2013) Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 73:824–833CrossRef

10.

Jin T, Yu CX, Jin T, Yu CX, Lei DP, Liu DY, Xu FL, Lu YT, Pan XL (2009) Identification of epidermal growth factor receptor (EGFR) exon 20 single nucleotide polymorphism in Chinese squamous cell carcinoma of head and neck (SCCHN). Acta Otolaryngol 129:1306–1312CrossRef

11.

Feng X, Qin JJ, Zheng BS, Huang LL, Xie XY, Zhou HF (2014) Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review. J Recept Signal Transduct Res 34:333–334CrossRef

12.

Moriai T, Kobrin MS, Korc M (1993) Cloning of a variant epidermal growth factor receptor. Biochem Biophys Res Commun 191:1034–1039CrossRef

13.

Moriai T, Kobrin MS, Hope C, Speck L, Korc M (1994) A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A 91:10217–10221CrossRef

14.

Datta NR, Stutz E, Liu M, Rogers S, Klingbiel D, Siebenhuner A, Singh S, Bodis S (2017) Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: a systematic review and meta-analysis. Gynecol Oncol 145:374–385CrossRef

15.

Bandres E, Barricarte R, Cantero C, Honorato B, Malumbres R, Zarate R, Alcalde J, Garcia-Foncillas J (2007) Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. Oral Oncol 43:713–719CrossRef

16.

Stoehlmacher-Williams J, Obermann L, Ehninger G, Goekkurt E (2012) Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC). Anticancer Res 32:421–425PubMed

17.

Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz HJ (2008) Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res 68:3037–3042CrossRef

18.

Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, Yun J, Press OA, Vallbohmer D, Rhodes K, Lenz HJ (2005) Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 11:600–605PubMed

19.

Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M, Soh J, Asano H, Ichimura K, Aoe K, Aoe M, Kiura K, Shimizu K, Date H, Shimizu N (2007) The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120:1239–1247CrossRef

20.

Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF (2007) Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 4:e125CrossRef

21.

Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC (2008) Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 8:129–138CrossRef

22.

Costa BM, Viana-Pereira M, Fernandes R, Costa S, Linhares P, Vaz R, Pinheiro C, Lima J, Soares P, Silva A, Pardal F, Amorim J, Nabico R, Almeida R, Alegria C, Pires MM, Pinheiro C, Carvalho E, Oliveira P, Lopes JM, Reis RM (2011) Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol Biomark Prev 20:2610–2617CrossRef

23.

Demirci S, Ozsaran Z, Ozsaran A, Yavas F, Demircioglu B, Hanhan M, Dikmen Y, Aras AB (2012) Evaluation of treatment results and prognostic factors in early-stage cervical carcinoma patients treated with postoperative radiotherapy or radiochemotherapy. Eur J Gynaecol Oncol 33:62–67PubMed

24.

Lee WM, Park SI, Kim BJ, Kim MH, Choi SC, Lee ED, Ryu SY (2012) Clinicopathologic factors for central recurrence in patients with locally advanced bulky cervical cancer. Eur J Obstet Gynecol Reprod Biol 161:219–223CrossRef

25.

Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, Lee SP, Hong JH (2012) Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys 84:420–427CrossRef

26.

Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in Cancer. Nucleic Acids Res 39:D945–D950CrossRef

27.

Hodoglugil U, Carrillo MW, Hebert JM, Karachaliou N, Rosell RC, Altman RB, Klein TE (2013) PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. Pharmacogenet Genomics 23:636–642CrossRef

28.

Liu W, He L, Ramirez J, Krishnaswamy S, Kanteti R, Wang YC, Salgia R, Ratain MJ (2011) Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res 71:2423–2427CrossRef

29.

Sasaki H, Okuda K, Shimizu S, Takada M, Kawahara M, Kitahara N, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Kubo A, Kawano O, Yukiue H, Yano M, Fujii Y (2009) EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol 135:313–318CrossRef

30.

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Network TR (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477CrossRef

31.

Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM (2018) Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development. Cancer Cell 34:163–177 e167CrossRef

32.

Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonzalez I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sanchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C (2015) Emergence of multiple EGFR extracellular mutations during Cetuximab treatment in colorectal Cancer. Clin Cancer Res 21:2157–2166CrossRef

33.

Goncalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, Monges G, Bertucci F, Esterni B, Delpero JR, Turrini O, Lelong B, Viens P, Borg JP, Birnbaum D, Olschwang S, Viret F (2008) A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 8:169CrossRef

Title: The Association between Epidermal Growth Factor Receptor Single Nucleotide Polymorphisms and Radiochemotherapy Response in Cervical Cancer
Authors: Ge Jin
Xiao-Mei Fan
Kui-Xiu Li
Shu-Huai Niu
Qian-Ying Zhang
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Metastasis
Cervical Cancer
Cervical Cancer
Radiotherapy
Cytostatic Therapy
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00690-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma

Comparison of CDH1 Gene Hypermethylation Status in Blood and Serum among Gastric Cancer Patients

Evaluation of Alpha 1-Antitrypsin for the Early Diagnosis of Colorectal Cancer

Aspirin Use and Risk of Glioma: a Double Track for a Single Goal?

KIBRA Team Up with Partners to Promote Breast Cancer Metastasis

Syndecan-1 in Liver Diseases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer